使用国际风险评分工具对帕利珠单抗预防加拿大中晚期早产儿严重RSV感染的成本效用影响

数据集获取（Figshare）

• 源站标题：Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants
• DOI：10.6084/m9.figshare.22645079.v2
• 发布日期：2023-05-02
• 文件数：2 个
• 文件总体积：1.11 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Impact_of_using_the_International_Risk_Scoring_Tool_on_the_cost-utility_of_palivizumab_for_preventing_severe_respiratory_syncytial_virus_infection_in_Canadian_moderate-to-late_preterm_infants/22645079

命令行下载

curl -L -o "ijme_a_2202600_sm4838.pdf" "https://ndownloader.figshare.com/files/40389487"
curl -L -o "ijme_a_2202600_sm5066.pdf" "https://ndownloader.figshare.com/files/40197692"

文件清单

• ijme_a_2202600_sm4838.pdf（515.90 KB）
• ijme_a_2202600_sm5066.pdf（594.62 KB）

文件总体积 1.11 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

To assess the cost-utility of palivizumab versus no prophylaxis in preventing severe respiratory syncytial virus (RSV) infection in Canadian moderate-to-late preterm (32–35 weeks’ gestational age) infants using an (i) International Risk Scoring Tool (IRST) and (ii) Canadian RST (CRST).
A decision tree was developed to assess cost-utility. Infants assessed at moderate- and high-risk of RSV-related hospitalization (RSVH) by the IRST or CRST received palivizumab or no prophylaxis and then progressed to either (i) RSVH; (ii) emergency room/outpatient medically attended RSV-infection (MARI) or (iii) were uninfected/non-medically attended. Infants admitted to intensive care could incur mortality (0.43%). Respiratory morbidity was accounted in all uninfected surviving infants for 6 years or 18 years (RSVH/MARI). Palivizumab efficacy (72.2% RSVH reduction) and hospital outcomes were from the Canadian CARESS, PICNIC and RSV-Quebec studies. Palivizumab costs (50 mg: CAN$752; 100 mg: $1,505) were calculated from Canadian birth statistics combined with a growth algorithm. Healthcare/payer and societal costs (May 2022; 1.5% discounting) were included.
Cost per quality-adjusted life year (QALY) was $29,789 with the IRST (0.79 probability of being Palivizumab was highly cost-effective (vs no prophylaxis) in Canadian moderate-to-late preterm infants using either the IRST or CRST. The IRST has fewer risk factors than the CRST (3 vs 7, respectively), captures more potential RSVHs (85% vs 54%) and provides another option to guide cost-effective RSV prophylaxis in Canada.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.22645079.v2（source: https://tandf.figshare.com/articles/dataset/Impact_of_using_the_International_Risk_Scoring_Tool_on_the_cost-utility_of_palivizumab_for_preventing_severe_respiratory_syncytial_virus_infection_in_Canadian_moderate-to-late_preterm_infants/22645079）。